Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.

Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G

Diabetologia11 Dec 2013Cited by 32 (Europe PMC)

PMID24326527PMCIDPMC5072364DOI10.1007/s00125-013-3134-3PepBankPUB-24326527

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, liraglutide increased the insulin secretion rate (21%) versus placebo (-4%).
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide raised insulin secretion more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion rate
Study
n = 49
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Insulin secretion rate change
21%
liraglutide
Insulin secretion rate change
−4%
placebo
Source sentences
Summary
Liraglutide treatment (n = 24) significantly (p ≤ 0.03) increased the insulin secretion rate (% mean change [95% CI]; 21% [12, 31] vs -4% [-11, 3]) and pancreatic beta cell sensitivity to intravenous glucose (229% [161, 276] vs -0.5% (-15, 14]), and decreased insulin clearance rate (-3.5% [-11, 4] v…
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652701
02HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, liraglutide increased beta cell sensitivity to intravenous glucose (229%) versus placebo (-0.5%).
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide made insulin-producing cells more responsive to glucose than placebo did.
Peptide
Liraglutide
Outcome
IncreaseBeta cell sensitivity to intravenous glucose
Study
n = 49
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Beta cell sensitivity change
229%
liraglutide
Beta cell sensitivity change
−0.5%
placebo
Source sentences
Summary
Liraglutide treatment (n = 24) significantly (p ≤ 0.03) increased the insulin secretion rate (% mean change [95% CI]; 21% [12, 31] vs -4% [-11, 3]) and pancreatic beta cell sensitivity to intravenous glucose (229% [161, 276] vs -0.5% (-15, 14]), and decreased insulin clearance rate (-3.5% [-11, 4] v…
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652702
03HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, liraglutide decreased the insulin clearance rate (-3.5%) versus placebo (8.2).
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide lowered how fast insulin was cleared compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin clearance rate
Study
n = 49
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Insulin clearance rate change
−3.5%
liraglutide
Insulin clearance rate change
8.2
placebo
Source sentences
Summary
Liraglutide treatment (n = 24) significantly (p ≤ 0.03) increased the insulin secretion rate (% mean change [95% CI]; 21% [12, 31] vs -4% [-11, 3]) and pancreatic beta cell sensitivity to intravenous glucose (229% [161, 276] vs -0.5% (-15, 14]), and decreased insulin clearance rate (-3.5% [-11, 4] v…
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652703
04HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, liraglutide lowered day-long glucose (-8.2%) versus placebo (-0.1) after mixed meals.
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide lowered blood glucose across the day after meals more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseDay-long glucose after mixed meals
Study
n = 49
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Day-long glucose change
−8.2%
liraglutide
Day-long glucose change
−0.1
placebo
Source sentences
Summary
The liraglutide-treated group also had significantly (p ≤ 0.03) lower day-long glucose (-8.2% [-11, -6] vs -0.1 [-3, 2]) and NEFA concentrations (-14 [-20, -8] vs -2.1 [-10, 6]) following mixed meals, whereas day-long insulin concentrations did not significantly differ as compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652704
05HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, liraglutide lowered day-long NEFA concentrations (-14) versus placebo (-2.1) after mixed meals.
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide lowered blood fatty acids across the day after meals more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseDay-long NEFA after mixed meals
Study
n = 49
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Day-long NEFA change
−14
liraglutide
Day-long NEFA change
−2.1
placebo
Source sentences
Summary
The liraglutide-treated group also had significantly (p ≤ 0.03) lower day-long glucose (-8.2% [-11, -6] vs -0.1 [-3, 2]) and NEFA concentrations (-14 [-20, -8] vs -2.1 [-10, 6]) following mixed meals, whereas day-long insulin concentrations did not significantly differ as compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652705
06HumanRandomized controlled trialEfficacy outcome
In overweight adults with prediabetes on an energy-restricted diet, day-long insulin concentrations did not differ significantly between liraglutide and placebo.
In plain wordsIn overweight adults with prediabetes on a diet, liraglutide did not clearly change blood insulin across the day compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeDay-long insulin concentrations after mixed meals
Study
n = 49
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
whereas day-long insulin concentrations did not significantly differ as compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652706
07HumanRandomized controlled trialMechanism
In overweight adults with prediabetes, weight loss was associated with lower insulin secretion rate in the placebo group but not in the liraglutide group.
In plain wordsIn overweight adults with prediabetes, weight loss was linked to lower insulin secretion with placebo, but no such link was seen with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeAssociation of weight loss with insulin secretion in the liraglutide group
Study
n = 24
Comparator
Placebo group
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
In a multivariate regression analysis, weight loss was associated with a decrease in insulin secretion rate and day-long glucose and insulin concentrations in the placebo group (p ≤ 0.05), but there was no association with weight loss in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652707
08HumanRandomized controlled trialSafety outcome
In overweight adults with prediabetes, nausea was the most common side effect of liraglutide.
In plain wordsIn overweight adults with prediabetes, nausea was the most common side effect of liraglutide.
Peptide
Liraglutide
Outcome
Not applicableMost common side effect (nausea)
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The most common side effect of liraglutide was nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals who were 40-70 years old, overweight (BMI 27-40 kg/m(2)) and with prediabetes were randomised (via a computerised system) to receive liraglutide (n = 35) or matching placebo (n = 33), and 49 participants were analysed.
Report a problemFND-2432652708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01784965

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Stanford Universityn = 69Dec 2009 to Dec 2012

Pre-diabetes · Older Adults

Trial page ClinicalTrials.govUpdated 21 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.